Skip to main content

16 Updates, Four New Recommendations Issued for Management of Pediatric VTE

Medically reviewed by Carmen Pope, BPharm. Last updated on May 30, 2025.

By Elana Gotkine HealthDay Reporter

FRIDAY, May 30, 2025 -- In clinical guidelines issued by the American Society of Hematology and the International Society on Thrombosis and Haemostasis, and published online May 27 in Blood Advances, new and updated recommendations are presented for the treatment of pediatric venous thromboembolism (VTE).

Paul Monagle, M.D., M.B.B.S., from the University of Melbourne in Australia, and colleagues developed evidence-based guidelines to support patients, clinicians, and other health care professionals in decisions regarding management of pediatric patients with VTE.

The authors updated 16 recommendations and added four new recommendations. These include suggested use of anticoagulation rather than no anticoagulation for pediatric patients with symptomatic deep vein thrombosis (DVT) or pulmonary embolism (PE) (conditional recommendation). Use of anticoagulation or no anticoagulation is suggested for pediatric patients with clinically unsuspected (asymptomatic) DVT or PE (conditional recommendation). Six weeks of anticoagulation is suggested rather than three months for select pediatric patients with provoked VTE (conditional recommendation). Anticoagulation is suggested for six to 12 months rather than indefinitely for pediatric patients with unprovoked DVT or PE (conditional recommendation). Direct oral anticoagulants (rivaroxaban/dabigatran) are suggested over standard of care anticoagulants (low molecular weight heparin, unfractionated heparin, vitamin K antagonist, or fondaparinux) for pediatric patients with VTE (conditional recommendation). Use of either rivaroxaban or dabigatran is suggested for pediatric patients with VTE, with individual populations or jurisdictional availability leading clinicians to choose one over the other.

"The care of children is important, and parents should know that there is a body of evidence that supports their child's treatment options," Monagle said in a statement.

Several authors disclosed ties to the biopharmaceutical industry.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Posted May 2025

Read this next

18.6 Million Cancer Survivors in the United States as of Jan. 1, 2025

FRIDAY, May 30, 2025 -- The number of cancer survivors in the United States reached 18.6 million as of Jan. 1, 2025, and is projected to exceed 22 million by 2035, according to a...

Longer In-Bed Time Linked to Small Vessel Disease Burden in TIA/Mild Stroke

FRIDAY, May 30, 2025 -- For adult patients with transient ischemic attack (TIA)/mild stroke, disturbed sleep is associated with greater cerebral small vessel disease (SVD) burden...

Prevalence of Disability Up Over Twofold for Current Smokers

FRIDAY, May 30, 2025 -- The prevalence of disability among adults who currently smoke cigarettes is more than twofold higher than that seen for never smokers, according to a study...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.